Alaseem, A.M.; Alhazzani, K.; Alanazi, A.Z.; Alqarni, Y.; Algahtani, M.M.; Alhamed, A.S.; Alasiri, G.; Alotaibi, F.T.; Jawaid, T.; Aldali, J.A.
Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment. Sci. Pharm. 2023, 91, 12.
https://doi.org/10.3390/scipharm91010012
AMA Style
Alaseem AM, Alhazzani K, Alanazi AZ, Alqarni Y, Algahtani MM, Alhamed AS, Alasiri G, Alotaibi FT, Jawaid T, Aldali JA.
Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment. Scientia Pharmaceutica. 2023; 91(1):12.
https://doi.org/10.3390/scipharm91010012
Chicago/Turabian Style
Alaseem, Ali M., Khalid Alhazzani, Ahmed Zuwaiel Alanazi, Yasser Alqarni, Mohammad M. Algahtani, Abdullah S. Alhamed, Glowi Alasiri, Fahad T. Alotaibi, Talha Jawaid, and Jehad A. Aldali.
2023. "Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment" Scientia Pharmaceutica 91, no. 1: 12.
https://doi.org/10.3390/scipharm91010012
APA Style
Alaseem, A. M., Alhazzani, K., Alanazi, A. Z., Alqarni, Y., Algahtani, M. M., Alhamed, A. S., Alasiri, G., Alotaibi, F. T., Jawaid, T., & Aldali, J. A.
(2023). Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment. Scientia Pharmaceutica, 91(1), 12.
https://doi.org/10.3390/scipharm91010012
